Tsuji, Akihito http://orcid.org/0000-0003-4034-1945
Nakamura, Masato
Watanabe, Takanori
Manaka, Dai
Matsuoka, Hiroshi
Kataoka, Masato
Takeuchi, Masahiro
Ichikawa, Wataru
Fujii, Masashi
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09
https://doi.org/10.1007/s11523-021-00845-y
Article History
Accepted: 20 September 2021
First Online: 31 October 2021
Declarations
:
: This work was supported by the JACCRO and funded by Takeda Pharmaceutical Co., Ltd.
: A.T. and W.I. have received grants from Takeda Pharmaceutical Co., Ltd. M.N., T.W., D.M., H.M., M.K., M.T., and M.F. declare that they have no conflicts of interest that might be relevant to the contents of this article.
: This study has been reviewed and approved by the JACCRO Institutional Review Board (No.2013-7).
: Written, informed consent was obtained from all study participants.
: Not applicable.
: Not applicable.
: Not applicable.
: AT, WI, and MF analyzed and interpreted patient data and contributed significantly to the writing of the manuscript. All authors enrolled patients, treated them, participated in manuscript preparation, and read and approved the final manuscript.